- Q4 reported sales increased 14%, core sales up 5%.
- Q4 net income decreased 26% to $74 million.
- Annual net income rose 5% to $393 million.
- Board approved $600 million stock repurchase.
Fourth Quarter 2025 Performance
AptarGroup reported a 14% increase in reported sales and a 5% rise in core sales for Q4 2025. However, net income fell by 26% to $74 million, with reported earnings per share decreasing by 24% to $1.13. Adjusted earnings per share were $1.25, and the adjusted EBITDA margin dropped to 8% from 23% the previous year. The company returned $206 million to shareholders through share repurchases and dividends. The Board approved a new $600 million stock repurchase authorization.
Annual 2025 Overview
For the full year, reported sales increased by 5%, and core sales rose by 2%. Net income grew by 5% to $393 million, with earnings per share up 7% to $5.89. AptarGroup returned $486 million to shareholders through share repurchases and dividends. Capital expenditures decreased, ending the year at about 7% of sales. The company marked its 32nd consecutive year of paying an annually increasing dividend.
Segment Highlights
All three segments showed core sales growth. The Pharma segment benefited from strong demand for elastomeric components and nasal drug delivery technologies. The Beauty segment achieved double-digit growth due to high demand for dispensing technologies. The Closures segment experienced strong product volume growth. Despite strong sales, a mix of products and higher production costs impacted overall profitability.
